REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Study sponsor: Inovio Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-07-08Actual
Enrollment · participants201Actual
Source updated2023-07-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.